Spyre Therapeutics (SYRE) Total Non-Current Liabilities (2015 - 2026)

Spyre Therapeutics (SYRE) has 12 years of Total Non-Current Liabilities data on file, last reported at $91.9 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 29.96% year-over-year to $91.9 million; the trailing twelve-month figure through Mar 2026 stood at $91.9 million (up 29.96% YoY), and the FY2025 full-year result was $35.9 million, down 33.66% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $91.9 million, up from $35.9 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $91.9 million in Q1 2026 and bottomed at $20.8 million in Q4 2022.
• The 5-year median for Total Non-Current Liabilities is $43.8 million (2023), against an average of $47.4 million.
• The widest annual swing landed in 2023, when Total Non-Current Liabilities jumped 294.3%; it then slumped 75.12% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $20.8 million in 2022, then jumped by 53.45% to $32.0 million in 2023, then surged by 69.05% to $54.1 million in 2024, then plunged by 33.66% to $35.9 million in 2025, then soared by 156.1% to $91.9 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $91.9 million (Q1 2026), $35.9 million (Q4 2025), and $46.3 million (Q3 2025), per Business Quant data.

Peer Comparison